APA

Finan K. M., Hodge G., Reynolds A. M., Hodge S., Holmes M. D., Baker A. H. & Reynolds P. N. (112016). Corrigendum to "In vitro susceptibility to the pro-apoptotic effects of TIMP-3 gene delivery translates to greater in vivo efficacy versus gene delivery for TIMPs-1 or -2" [Lung Cancer 53 (3) (September 2006) 273-284]. : Lung cancer (Amsterdam, Netherlands).

Chicago

Finan Katherine M, Hodge Greg, Reynolds Ann M, Hodge Sandra, Holmes Mark D, Baker Andrew H and Reynolds Paul N. 112016. Corrigendum to "In vitro susceptibility to the pro-apoptotic effects of TIMP-3 gene delivery translates to greater in vivo efficacy versus gene delivery for TIMPs-1 or -2" [Lung Cancer 53 (3) (September 2006) 273-284]. : Lung cancer (Amsterdam, Netherlands).

Harvard

Finan K. M., Hodge G., Reynolds A. M., Hodge S., Holmes M. D., Baker A. H. and Reynolds P. N. (112016). Corrigendum to "In vitro susceptibility to the pro-apoptotic effects of TIMP-3 gene delivery translates to greater in vivo efficacy versus gene delivery for TIMPs-1 or -2" [Lung Cancer 53 (3) (September 2006) 273-284]. : Lung cancer (Amsterdam, Netherlands).

MLA

Finan Katherine M, Hodge Greg, Reynolds Ann M, Hodge Sandra, Holmes Mark D, Baker Andrew H and Reynolds Paul N. Corrigendum to "In vitro susceptibility to the pro-apoptotic effects of TIMP-3 gene delivery translates to greater in vivo efficacy versus gene delivery for TIMPs-1 or -2" [Lung Cancer 53 (3) (September 2006) 273-284]. : Lung cancer (Amsterdam, Netherlands). 112016.